Porcilis PCV M Hyo

RSS

porcine circovirus (inactivated) and porcine enzootic pneumonia vaccine

Authorised
This medicine is authorised for use in the European Union.

Overview

An overview of Porcilis PCV M Hyo and why it is authorised in the EU

Porcilis PCV M Hyo is a veterinary vaccine used to protect pigs against two separate infections, caused by porcine circovirus and Mycoplasma hyopneumoniae.

  • Porcine circovirus type 2 (PCV2) infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, diarrhoea, pale skin and jaundice (yellowing of the skin).
  • Infection with the bacterium Mycoplasma hyopneumoniae in pigs causes a disease of the airways called enzootic pneumonia. Affected pigs often have a cough and fail to thrive.

Porcilis PCV M Hyo contains porcine circovirus type 2 (PCV2) subunit antigen (a protein derived from part of the virus) and an inactivated (killed) strain of Mycoplasma hyopneumoniae bacteria.

This EPAR was last updated on 04/09/2018

Authorisation details

Product details
Name
Porcilis PCV M Hyo
Agency product number
EMEA/V/C/003796
Active substance
Porcine circovirus type 2 (PCV2) ORF2 subunit antigen, Mycoplasma hyopneumoniae J strain inactivated
International non-proprietary name (INN) or common name
porcine circovirus (inactivated) and porcine enzootic pneumonia vaccine
Species
Pigs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI09AL
Publication details
Marketing-authorisation holder
Intervet International B.V.
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
06/11/2014
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

27/06/2018 Porcilis PCV M Hyo - EMEA/V/C/003796 - II/0007

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Inactivated viral and inactivated bacterial vaccines for pigs

Therapeutic indication

For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (PCV2) infection, and severity of lung lesions caused by Mycoplasma hyopneumoniae infection. To reduce the loss of daily weight gain during the finishing period in face of infections with Mycoplasma hyopneumoniae and/or PCV2 (as observed in field studies).

Assessment history

How useful was this page?

Add your rating